Joseph R. Mace

2.8k total citations
23 papers, 560 citations indexed

About

Joseph R. Mace is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Joseph R. Mace has authored 23 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in Joseph R. Mace's work include Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Joseph R. Mace is often cited by papers focused on Multiple Myeloma Research and Treatments (9 papers), Protein Degradation and Inhibitors (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Joseph R. Mace collaborates with scholars based in United States, France and Canada. Joseph R. Mace's co-authors include J. Sybil Biermann, Vernon K. Sondak, Dafydd G. Thomas, Curtis W. Hayes, Cornelius J. McGinn, Edward Arrowsmith, Lowell L. Hart, Ian W. Flinn, John D. Hainsworth and Zachary M. Soler and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Joseph R. Mace

23 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph R. Mace United States	10	215	206	180	163	118	23	560
Hayley Robinson United States	6	233 1.1×	307 1.5×	66 0.4×	308 1.9×	59 0.5×	8	718
Kenneth J. Craddock Canada	12	261 1.2×	250 1.2×	54 0.3×	162 1.0×	124 1.1×	28	618
Emanuela Virdis Italy	8	152 0.7×	433 2.1×	230 1.3×	129 0.8×	23 0.2×	10	589
Marcel Trautmann Germany	19	181 0.8×	430 2.1×	171 0.9×	216 1.3×	19 0.2×	48	781
Teruto Isayama Japan	16	216 1.0×	433 2.1×	214 1.2×	111 0.7×	23 0.2×	34	624
Eisuke Shiba Japan	11	173 0.8×	227 1.1×	127 0.7×	80 0.5×	42 0.4×	26	476
Kristin Andersen Norway	13	98 0.5×	137 0.7×	104 0.6×	246 1.5×	35 0.3×	55	499
Kathrin Radig Germany	16	209 1.0×	394 1.9×	187 1.0×	181 1.1×	21 0.2×	30	590
Avery A. Sandberg United States	15	120 0.6×	412 2.0×	158 0.9×	217 1.3×	43 0.4×	22	643
Raffaello Bertieri Italy	7	264 1.2×	225 1.1×	235 1.3×	88 0.5×	275 2.3×	7	766

Countries citing papers authored by Joseph R. Mace

Since Specialization

Citations

This map shows the geographic impact of Joseph R. Mace's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph R. Mace with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph R. Mace more than expected).

Fields of papers citing papers by Joseph R. Mace

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph R. Mace. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph R. Mace. The network helps show where Joseph R. Mace may publish in the future.

Co-authorship network of co-authors of Joseph R. Mace

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph R. Mace. A scholar is included among the top collaborators of Joseph R. Mace based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph R. Mace. Joseph R. Mace is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Façon, Thierry, Shaji Kumar, Torben Plesner, et al.. (2022). Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.. Journal of Clinical Oncology. 40(16_suppl). 8044–8044. 2 indexed citations

Berdeja, Jesús G., Tara Gregory, Edward A. Faber, et al.. (2021). A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort. American Journal of Hematology. 96(4). 428–435. 13 indexed citations

Flinn, Ian W., et al.. (2019). Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy. The Oncologist. 24(8). 1035–e623. 9 indexed citations

Berdeja, Jesús G., Edward A. Faber, Jeffrey Matous, et al.. (2016). A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion. Blood. 128(22). 4530–4530. 6 indexed citations

Hainsworth, John D., James A. Reeves, Joseph R. Mace, et al.. (2016). A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Targeted Oncology. 11(5). 643–653. 54 indexed citations

Schlosser, Rodney J., Timothy L. Smith, Joseph R. Mace, & Zachary M. Soler. (2016). Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy. 72(3). 483–491. 51 indexed citations

Bendell, Johanna C., Howard S. Höchster, Lowell L. Hart, et al.. (2015). A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(3_suppl). 663–663. 6 indexed citations

Hart, Lowell L., Joseph R. Mace, Edward Arrowsmith, et al.. (2015). Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 100(5). 670–676. 79 indexed citations

Berdeja, Jesús G., Tara Gregory, Jeffrey Matous, et al.. (2015). A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).. Journal of Clinical Oncology. 33(15_suppl). 8513–8513. 5 indexed citations

10.

Berdeja, Jesús G., Edward A. Faber, Jeffrey Matous, et al.. (2015). A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts. Blood. 126(23). 1825–1825. 6 indexed citations

11.

Hainsworth, John D., Joseph R. Mace, James A. Reeves, et al.. (2015). Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 33(15_suppl). 4547–4547. 7 indexed citations

12.

Bonomi, Philip, Joseph R. Mace, Romeo A. Mandanas, et al.. (2013). Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(3). 338–345. 14 indexed citations

13.

Berdeja, Jesús G., Michael R. Savona, Joseph R. Mace, et al.. (2013). A Single-Arm, Open-Label, Multi-Center Phase I/II Study Of The Combination Of Panobinostat and Carfilzomib In Patients (pts) With Relapsed Or Relapse/Refractory Multiple Myeloma (MM). Blood. 122(21). 1937–1937. 8 indexed citations

14.

Berdeja, Jesús G., Joseph R. Mace, Victor G. Gian, et al.. (2012). A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).. Journal of Clinical Oncology. 30(15_suppl). TPS8115–TPS8115. 3 indexed citations

15.

Mace, Joseph R.. (2012). Radioimmunotherapy in follicular lymphoma: an update.. PubMed. 10(6). 394–6. 2 indexed citations

16.

Bonomi, Philip, et al.. (2009). Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 8046–8046. 1 indexed citations

17.

Conlin, Alison, A. D. Seidman, Mary Ellen Moynahan, et al.. (2007). Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report. Journal of Clinical Oncology. 25(18_suppl). 1104–1104. 8 indexed citations

18.

Chugh, Rashmi, Rodney L. Dunn, Mark M. Zalupski, et al.. (2005). Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma. Journal of Clinical Oncology. 23(15). 3597–3604. 71 indexed citations

19.

Mace, Joseph R., Mary Lou Keohan, Klaus Junge, et al.. (2003). Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.. PubMed. 9(16 Pt 1). 5829–34. 14 indexed citations

20.

Mace, Joseph R., J. Sybil Biermann, Vernon K. Sondak, et al.. (2002). Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 95(11). 2373–2379. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact